ASCO 2024: Addressing Unmet Needs in Early Breast Cancer

Avan J. Armaghani, MD

May 23, 2024

Avan J. Armaghani, MD, looks ahead at updates to be presented at the ASCO 2024 Annual Meeting. Of particular interest are discussions surrounding patients with triple-negative breast cancer with residual disease post-neoadjuvant therapy, shedding light on adjuvant options like the A-BRAVE trial's investigation into avelumab's efficacy.

Dr Armaghani also looks forward to insights into the clinical utility of ctDNA, hoping for clearer guidelines on its use in recurrence monitoring and treatment decision-making.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASCO 2024: Addressing Unmet Needs in Early Breast Cancer - Medscape - May 23, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

ASCO 2024: Addressing Unmet Needs in Early Breast Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Avan J. Armaghani, MD

Comments

Email This

Feedback